Clincosm LogoSign in Get a demo

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Sponsor
Third Military Medical University (Other)
Overall Status
Unknown status
CT.gov ID
NCT01629225
Collaborator
(none)
500
Enrollment
1
Location
1
Arm
24
Duration (Months)
20.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
500 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Study Start Date :
Jul 1, 2013
Anticipated Primary Completion Date :
Jul 1, 2015
Anticipated Study Completion Date :
Jul 1, 2015

Arms and Interventions

Arm Intervention/Treatment
No Intervention: candesartan

All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.

Drug: Candesartan
To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
Other Names:
  • GRK4 polymorphisms and essential hypertrension

    		•

    Outcome Measures

    Primary Outcome Measures

    1. The subjects with GRK4 varirants may exert different response during 4 weeks of treatment with candesartan in patients with essential hypertension [two years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    30 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • men and women with mild to moderate essential hypertension in southwestern Han Chinese
    Exclusion Criteria:

    • subjects unwilling to participate or subjects did not have all measurement required,

    • subjects who were on medications, which affect blood pressure or

    • whose DNA failed to amplify and 8 with errors in Mendelian segregation

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Cardiology, Daping Hospital, The Third Military Medical University Chongqing China 400042

    Sponsors and Collaborators

    • Third Military Medical University

    Investigators

    • Study Director: Zeng Chunyu, Doctor, TMMU

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Yu Changqing, Department of Cardiovascular Diseases; Institute of Cardiovascular Diseases; Daping Hospital;, Third Military Medical University
    ClinicalTrials.gov Identifier:
    NCT01629225
    Other Study ID Numbers:
    • ThirdMMU
    First Posted:
    Jun 27, 2012
    Last Update Posted:
    Nov 18, 2014
    Last Verified:
    Jun 1, 2013
    Keywords provided by Yu Changqing, Department of Cardiovascular Diseases; Institute of Cardiovascular Diseases; Daping Hospital;, Third Military Medical University
    men and women
    in southwestern Han Chinese
    Additional relevant MeSH terms:
    Essential Hypertension
    Candesartan

    Study Results

    No Results Posted as of Nov 18, 2014